ClinicalTrials.gg
CompletedNCT04676256EVIDENSEUpdated Feb 20, 2026

Early VItrectomy in DENse Spontaneous Vitreous HEmorrhage

An interventional study of Early vitrectomy in Spontaneous Vitreous Hemorrhage, Retinal Break and Retinal Detachment, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Read the detailed description

The aim of the protocol is to compare the ocular outcomes after spontaneous vitreous hemorrhage treated with an early vitrectomy versus ultrasound monitoring with late vitrectomy.

The hypothesis is that an early vitrectomy could decrease the rate of retinal detachment occurring after a spontaneous vitreous hemorrhage.

Scientific background Spontaneous vitreous hemorrhage may occur after spontaneous posterior vitreous detachment and causes retinal break and retinal detachment in about 70% and 40% of cases respectively. The fundus examination and ultrasound have limited sensitivity to detect retinal breaks in these cases. Some retrospective studies have highlighted the benefit of an early vitrectomy for decreasing the rate of visual loss due to retinal detachment in these cases. However, to date, there is no national or international consensus regarding the management of spontaneous vitreous hemorrhage and the timing of vitrectomy.

Study design Prospective randomized clinical trial Primary objective To compare the results of an early vitrectomy versus ultrasound and fundus observation in spontaneous vitreous hemorrhage.

Secondary objectives To evaluate the rate of retinal complications in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

To evaluate the rate of visual loss in spontaneous vitreous hemorrhage treated either with early or delayed vitrectomy.

Primary criteria Rate of retinal detachment in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Secondary criteria Rate of retinal breaks and vitreo-retinal proliferation in eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Visual acuity and rate of eyes with a loss of 5 letters or more among eyes with spontaneous vitreous hemorrhage treated with early vitrectomy versus ultrasound observation at 6-month follow-up Participants Patients with a spontaneous vitreous hemorrhage secondary to posterior vitreous detachment, with a reduced visibility of the fundus Inclusion criteria

  • Age > or = 18 years old
  • Spontaneous vitreous hemorrhage which is 1/ secondary to posterior vitreous detachment; 2/ acute: which duration is \< 15 days, 3/ dense: reduced visibility of the fundus

Exclusion criteria:

  • Retinal detachment at the initial examination
  • Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
  • Any history of uveitis, age-related macular degeneration
  • History of a recent ocular traumatism (\< 3 months)
  • History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
  • Absence of consent Experimental group Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63) Active Comparator group Eyes with spontaneous vitreous hemorrhage only observed using fundus examination and B-ultrasound (n = 63) Study duration Inclusion: 12 months Participation: 6 months Total duration: 18 months
02

Conditions studied

  • Spontaneous Vitreous Hemorrhage
  • Retinal Break
  • Retinal Detachment

Keywords

  • spontaneous vitreous hemorrhage
  • retinal break
  • retinal detachment
  • ultrasound
  • vitrectomy
03

In context

Retinal Perforations

139 studies on the registry are indexed under Retinal Perforations; 22 are open to participants now.

This study's enrollment of 8 is below the median of 50 across 94 interventional studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > or = 18 years old
  • Spontaneous vitreous hemorrhage which is :

    1. secondary to posterior vitreous detachment;
    2. acute: which duration is \< 15 days,
    3. dense: reduced visibility of the fundus

Exclusion criteria

Exclusion Criteria:

  • Retinal detachment at the initial examination
  • Any history of vascular retinal disease (diabetic retinopathy, retinal vein occlusion…)
  • Any history of uveitis, age-related macular degeneration
  • History of a recent ocular traumatism (\< 3 months)
  • History of a recent retinal laser treatment (\< 3 months) or vitreo-retinal surgery (\< 3 months)
  • Absence of oral and written consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Early Vitrectomy

    Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis

    Procedure: Early vitrectomy

  • Active comparator
    Comparator

    Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed. Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up

    Procedure: Early vitrectomy

Interventions

  • ProcedureEarly vitrectomy

    Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

06

What researchers measure

Primary outcomes

  1. Rate of retinal detachment

    number of eyes with a retinal detachment in each group. The presence of retinal detachment will be assessed on fundus examination

    Time frame: 6 months after intervention

Secondary outcomes

  1. Rate of retinal breaks

    number of eyes with a retinal breaks in each group. The presence of retinal breaks will be assessed on fundus examination

    Time frame: 6 months after intervention

  2. Rate vitreo-retinal proliferation

    number of eyes with a vitreo-retinal proliferation in each group. The presence of vitreo-retinal proliferation will be assessed on fundus examination

    Time frame: 6 months after intervention

  3. Visual acuity

    visual acuity will be measured using Snellen and/or ETDRS chart

    Time frame: 6 months after intervention

  4. Rate of eyes with a loss of 5 letters or more

    Time frame: 6 months after intervention

  5. Rate of cataract

    Time frame: 6 months after intervention

07

Study locations

1 site
  • Hopital Lariboisiere
    Paris, Île-de-France Region 75010, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2024, 35 months.

Of 45 non-industry interventional studies with no phase under Retinal Perforations, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 35 months is above that.

Counting every sponsor, half of 45 studies reached it within 28 months; a quarter within 12 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2020
First posted
Dec 21, 2020
StartActual
Jul 2, 2021
Primary completionActual
Jun 27, 2024
CompletionActual
Jun 27, 2024
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04676256
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Jul 2, 2021
Primary completion
Jun 27, 2024
Completion
Jun 27, 2024
Last update
Feb 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion